| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.1 |
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.051 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.079 | 0.1 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.043 | 0.1 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.1 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.1 |